VoyForums
GIVE FREE FOOD
www.TheHungerSite.com
-> Click Here <-
Fund Free Mammograms with a Click
www.TheBreastCancerSite.com
-> Click Here <-
Non-profit ad served by VoyForums...

VoyUser Login optional ] [ Contact Forum Admin ] [ Main index ] [ Post a new message ] [ Search | Check update time | Archives: [1] ]


[ Next Thread | Previous Thread | Next Message | Previous Message ]

Date Posted: 09:27:30 04/07/05 Thu
Author: J. Cramer
Subject: ANTHRAX ALERT...This Will Be Huge!

ANTHRAX ALERT...This Will Be Huge!

Get in on the ground floor while the stock is still cheap! For more
info got to http://www.avanir.com

AVANIR's Anthrax Antibody Data Presented at 2005 ASM Biodefense
Research Meeting



SAN DIEGO--(BUSINESS WIRE--AVANIR Pharmaceuticals' (AMEX:AVN - News)
anti-anthrax monoclonal antibodies have demonstrated an ability to
protect against the most lethal form of anthrax toxins in animal
models. Data from additional studies conducted by Johnny W.
Peterson, Ph.D., of the University of Texas Medical Branch were
presented today in a poster entitled "Human Monoclonal Antibodies to
Protective Antigen with and without Ciprofloxacin Protect Mice and
Guinea Pigs against Inhalation Anthrax" at the 2005 American Society
for Microbiology (ASM) Biodefense Research Meeting being held this
week in Baltimore, Maryland.



"Human anti-PA monoclonal antibodies supplied by AVANIR
Pharmaceuticals have been shown to protect against lethal infection
in mice and guinea pigs challenged with B. anthracis spores
instilled into the respiratory tract," said Dr. Peterson. "Our
research indicates delay in death and survival is significantly
increased by co-administration of antibodies with low levels of
ciprofloxacin."

The in vivo tests on passive immunization with AVANIR human
monoclonal antibodies are being conducted in small animal models
established at the University of Texas Medical Branch in Galveston
under contract from the National Institute of Allergy and Infectious
Disease (NIAID), a division of the National Institutes of
Health. "AVANIR's human monoclonal antibodies to protective antigen
(PA), such as AVP-21D9, have high specificity and very desirable
binding properties, and offer considerable promise for the rapid
development of products useful as adjuncts to current antimicrobial
prophylaxis and therapy against inhalation anthrax," continued Dr.
Peterson.

Antibodies that neutralize anthrax toxins may augment existing
treatment options. Currently, a vaccine and antibiotics are the
treatment options available for the prevention or treatment of
anthrax exposure. Both approaches have limitations. The anthrax
vaccine takes weeks following the first doses before immunity is
established, and requires multiple injections over a period of
months, in addition to annual boosters, to reach and maintain its
protective effect. Antibiotics, the standard treatment of anthrax
infection, are effective in killing anthrax bacteria, but have no
effect on the anthrax toxins.

"These data indicate that AVP-21D9 may provide the necessary
immediate protection before other treatment regimens take effect,"
concluded Dr. Peterson.

AVANIR Pharmaceuticals is a drug discovery and development company
focused on treatments for chronic diseases. Our product candidates
address therapeutic markets that include central nervous system and
cardiovascular disorders, inflammation, and infectious disease. The
Company's first commercialized product, AbrevaŽ, is marketed in
North America by GlaxoSmithKline Consumer Healthcare and is the
leading over-the-counter product for the treatment of cold sores.
Further information about AVANIR can be found at www.avanir.com.

[ Next Thread | Previous Thread | Next Message | Previous Message ]

[ Contact Forum Admin ]


Forum timezone: GMT-8
VF Version: 3.00b, ConfDB:
Before posting please read our privacy policy.
VoyForums(tm) is a Free Service from Voyager Info-Systems.
Copyright © 1998-2017 Voyager Info-Systems. All Rights Reserved.